Commitments and Contingencies (Details) $ in Thousands		12 Months Ended
	Dec. 22, 2017 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Commitments and Contingencies [Line Items]
Royalty expense lower range		$ 25
Royalty expense upper range		75
Maximum additional milestone payments		775
Research and development expense		$ 24,989	$ 16,808
License Agreement Terms [Member]
Commitments and Contingencies [Line Items]
Number of research labs	50
Number of clinical research studies	2,500
Royalty terms	1.00%
Royalty terms sales	$ 100,000
Royalty terms additonal royalty	1.50%
Royalty net proceeds	12.50%
Royalty terms initial term	2 years
After agreement royalty net proceeds percentage	7.50%
New drug application milestones	$ 275
Terms of Iowa Agreement [Member]
Commitments and Contingencies [Line Items]
License agreement description		During the term of the services, the Company would generally pay the University of Iowa thirty thousand dollars ($30) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000 to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product up to $25,000: $62; for annual net sales of product of up to $50,000: $62; and for annual net sales of product of up to $100,000: $125.
Iowa Agreement [Member]
Commitments and Contingencies [Line Items]
Research and development expense		$ 27	$ 2
Feinstein Agreement [Member]
Commitments and Contingencies [Line Items]
Research and development expense		$ 15	$ 17